1. Home
  2. GRML

as of 11-13-2026 3:55pm EST

$3.63
$0.23
-5.96%
Stocks Nasdaq

Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.

Founded: N/A Country:
United States
United States
Employees: N/A City: OMAHA
Market Cap: 29.2M IPO Year: 2022
Target Price: N/A AVG Volume (30 days): 973.0K
Analyst Decision: N/A Number of Analysts: N/A
Dividend Yield:
N/A
Dividend Payout Frequency: annual
EPS: -0.16 EPS Growth: 31.25
52 Week Low/High: $0.16 - $18.21 Next Earning Date: 11-24-2026
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A
P/E Ratio: -24.13 Index: N/A
Free Cash Flow: N/A FCF Growth: N/A

Stock Insider Trading Activity of Greenland Mines Ltd. Common Stock (GRML)

GRML Oct 1, 2026

Avg Cost/Share

$9.35

Shares

3,500

Total Value

$32,727.10

Owned After

0

SEC Form 4

LeBlanc Jeff

Chief Financial Officer

Buy
GRML Aug 25, 2026

Avg Cost/Share

$9.72

Shares

14,000

Total Value

$136,080.00

Owned After

110,406

SEC Form 4

Share on Social Networks: